Arcturus Therapeutics Valuation
| ARCT Stock | USD 15.45 0.92 6.33% |
At this time, the firm appears to be overvalued. Arcturus Therapeutics shows a prevailing Real Value of $12.01 per share. The current price of the firm is $15.45. Our model approximates the value of Arcturus Therapeutics from analyzing the firm fundamentals such as profit margin of (0.47) %, and Return On Equity of -0.27 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Arcturus Therapeutics' valuation include:
Price Book 1.6858 | Enterprise Value | Enterprise Value Ebitda (25.67) | Price Sales 2.9163 | Forward PE 2.4777 |
Overvalued
Today
Please note that Arcturus Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Arcturus Therapeutics is based on 3 months time horizon. Increasing Arcturus Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Arcturus Therapeutics' intrinsic value may or may not be the same as its current market price of 15.45, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.45 | Real 12.01 | Target 67.1 | Hype 15.45 | Naive 14.46 |
The intrinsic value of Arcturus Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Arcturus Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Arcturus Therapeutics Holdings helps investors to forecast how Arcturus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arcturus Therapeutics more accurately as focusing exclusively on Arcturus Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Arcturus Therapeutics' intrinsic value based on its ongoing forecasts of Arcturus Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Arcturus Therapeutics' closest peers.
Arcturus Therapeutics Cash |
|
Arcturus Valuation Trend
Arcturus Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Arcturus Therapeutics' financial worth over time. Using both Arcturus Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Arcturus Revenue by Product
Arcturus Therapeutics Total Value Analysis
Arcturus Therapeutics Holdings is presently forecasted to have valuation of 219.77 M with market capitalization of 419.01 M, debt of 28.55 M, and cash on hands of 283.49 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Arcturus Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
219.77 M | 419.01 M | 28.55 M | 283.49 M |
Arcturus Therapeutics Investor Information
About 93.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.69. Some equities with similar Price to Book (P/B) outperform the market in the long run. Arcturus Therapeutics has Price/Earnings (P/E) ratio of 119.5. The entity recorded a loss per share of 2.52. The firm last dividend was issued on the 16th of November 2017. Arcturus Therapeutics had 1:7 split on the 16th of November 2017. Based on the key indicators related to Arcturus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Arcturus Therapeutics Holdings may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Arcturus Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Arcturus Therapeutics has an asset utilization ratio of 40.22 percent. This implies that the Company is making $0.4 for each dollar of assets. An increasing asset utilization means that Arcturus Therapeutics Holdings is more efficient with each dollar of assets it utilizes for everyday operations.Arcturus Therapeutics Ownership Allocation
Arcturus Therapeutics holds a total of 27.12 Million outstanding shares. The majority of Arcturus Therapeutics Holdings outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Arcturus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Arcturus Therapeutics. Please pay attention to any change in the institutional holdings of Arcturus Therapeutics Holdings as this could imply that something significant has changed or is about to change at the company. Also note that nearly two hundred seventy-three thousand nine hundred eighteen invesors are currently shorting Arcturus Therapeutics expressing very little confidence in its future performance.Arcturus Therapeutics Profitability Analysis
The company reported the previous year's revenue of 138.39 M. Net Loss for the year was (80.94 M) with loss before overhead, payroll, taxes, and interest of (32.8 M).About Arcturus Therapeutics Valuation
The stock valuation mechanism determines Arcturus Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Arcturus Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Arcturus Therapeutics. We calculate exposure to Arcturus Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Arcturus Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 134.8 M | 141.6 M | |
| Pretax Profit Margin | (0.58) | (0.61) | |
| Operating Profit Margin | (0.69) | (0.73) | |
| Net Loss | (0.58) | (0.61) | |
| Gross Profit Margin | 0.97 | 1.02 |
Arcturus Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Arcturus Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 27 M | |
| Forward Price Earnings | 2.4777 |
Arcturus Therapeutics Current Valuation Indicators
Arcturus Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Arcturus Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Arcturus Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Arcturus Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Arcturus Therapeutics' worth.Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.